...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >Elevation in Total Homocysteine Levels in Chinese Patients With Essential Hypertension Treated With Antihypertensive Benazepril
【24h】

Elevation in Total Homocysteine Levels in Chinese Patients With Essential Hypertension Treated With Antihypertensive Benazepril

机译：降压贝那普利治疗中国原发性高血压患者总同型半胱氨酸水平的升高

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To investigate the effect of benazepril on plasma homocysteine (Hcy) levels and to analyze the correlation between the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and changes in Hcy levels in response to benazepril. A total of 231 patients with mild to moderate essential hypertension were enrolled, and benazepril was orally administered at a dose of 10 mg/d for 2 weeks. Plasma Hcy levels were measured by high-performance liquid chromatography at baseline and after 2 weeks of treatment. Genotyping of the MTHFR C677T polymorphism was performed by TaqMan probe technique. There was no significant change in Hcy level after benazepril treatment for 2 weeks (P = .97). However, stratified by baseline Hcy levels, the patients with baseline Hcy P = .003). The results from the multivariable linear regression analysis demonstrated a significant correlation between baseline Hcy levels and the changes in Hcy levels found in both the unadjusted (P = .002) and the adjusted model (P = .004). Strikingly, we found no significant effect modification by the MTHFR C677T polymorphism on the Hcy changes after benazepril treatment. There were also no statistically significant interactions of gene and environment factors (ie, gene smoking and drinking) on the changes in Hcy levels after benazepril treatment. Benazepril may cause an increase in plasma Hcy levels among patients with hypertension with low baseline Hcy levels, while effect modification by MTHFR C677T genotypes on the changes in Hcy levels in response to benazepril was not significant among patients with essential hypertension.
机译：研究苯那普利对血浆高半胱氨酸（Hcy）水平的影响，并分析亚甲基四氢叶酸还原酶（MTHFR）C677T多态性与响应苯那普利的Hcy水平变化之间的相关性。总共纳入231名轻度至中度原发性高血压患者，并以10 mg / d的剂量口服苯那普利2周。在基线和治疗2周后，通过高效液相色谱法测定血浆Hcy水平。 MTHFR C677T多态性的基因分型通过TaqMan探针技术进行。苯那普利治疗2周后Hcy水平无明显变化（P = 0.97）。但是，按基线Hcy水平分层，基线Hcy P = .003的患者。多变量线性回归分析的结果表明，基线Hcy水平与未经调整的模型（P = .002）和经过调整的模型（P = .004）中的Hcy水平变化之间存在显着相关性。令人惊讶的是，我们发现贝那普利治疗后MTHFR C677T多态性对Hcy变化没有显着影响。苯那普利治疗后，Hcy水平的变化与基因和环境因素（即基因吸烟和饮酒）之间也没有统计学上的显着相互作用。贝那普利可能会导致基线Hcy水平低的高血压患者血浆Hcy水平升高，而原发性高血压患者中MTHFR C677T基因型对苯那普利的响应对Hcy水平变化的影响改变并不显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号